Bal Pharma launches BALflu, Favipiravir formulation in India
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
This achievement validates global demand and catapults Wanbury into high-growth acceleration
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
A PhD in Pharmaceutical Sciences, Dr Singh has led global regulatory audits, product validations, and quality systems spanning therapeutic formulations, dietary supplements, and functional foods
The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
Subscribe To Our Newsletter & Stay Updated